Clinical Trials Browser

Phase 1/2 × Anemia, Refractory, with Excess of Blasts × fludarabine × Clear all

Anemia, Refractory, with Excess of Blasts, Lymphoma, Hematologic Neoplasms

NCT06680752 2025-12-10

Clinical Study of ARD103 CAR-T Therapy for Patients With R/R AML or MDS

Phase 1/2 Recruiting

49 enrolled

Classical hematologyOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Leukemia, Myeloid, Acute

NCT01163201 2017-12-02

T-Regulatory Cell and CD3 Depleted Double Umbilical Cord Blood Transplantation in Hematologic Malignancies

Phase 1/2 Withdrawn

Classical hematologyLymphoidMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Burkitt Lymphoma, Lymphoma, Follicular, Myeloproliferative Disorders, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute, Lymphoma, B-Cell, Marginal Zone, Hematologic Neoplasms, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Clinical Trials

Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies

Clinical Study of ARD103 CAR-T Therapy for Patients With R/R AML or MDS

T-Regulatory Cell and CD3 Depleted Double Umbilical Cord Blood Transplantation in Hematologic Malignancies